http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102258773-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4873cd720f7e169a6f1bd1ed6b41c31a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72d257042432cdb0f005ec8c5ae6e7d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08b167f1c503e0832290c6be41cfa0dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cdf9b79b9edcd4589854c4d55da1f95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93980165846dc9f2096c55e27184b41b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e013c658df91745801ce9c284892c69e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_614ac5f9000deb1b911caf50a6fc3eab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb1061d3e338c76b81159fce338cc88 |
| publicationDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102258773-B |
| titleOfInvention | Mesylate protein kinase receptor EphA2 dominant epitope compound and preparation method and application thereof |
| abstract | The invention discloses a mesylate protein kinase receptor EphA2 dominant epitope compound and a preparation method and application thereof in preparing a therapeutic vaccine for tumor. The compound is prepared from EphA258-66 epitope fusion peptide, EphA2550-558 epitope fusion peptide and EphA2253-261 epitope fusion peptide in mol ratio of 1:1:1 and an LIGHT gene recombinant eukaryotic expression vector; the EphA258-66/550-558/253-261 epitope fusion peptides are respectively prepared from EphA258-66/550-558/253-261 epitopes and a transmembrane sequence HIV-Tat49-57, an endoplasmic reticulum retention signal sequence KDEL and a linker sequence AAY; the combination of the three EphA2 dominant epitopes can effectively overcome the deficiency of a single epitope on immune effect; the three epitope fusion peptides can enter the kytoplasm under the guide action of the transmembrane sequence, target the endoplasmic reticulum under the action of the endoplasmic reticulum retention signal sequence, and efficiently enter an MHC-I (major histocompatibility complex-class I) antigen presenting route; and the LIGHT gene recombinant eukaryotic expression vector can express LIGHT protein in vivoand play a role of a molecular adjuvant to promote the immune response of epitope specific T cells. |
| priorityDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 283.